Novel treatment for cancer patients
Novel treatment for cancer patients


CHICAGO, IL -- Indian American Prof. Sattva Neelapu and other researchers have developed a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

The novel treatment involves the CD19-targeting chimeric antigen receptor T-cell therapy for patients with aggressive large B-cell lymphoma–a blood cancer–who have failed prior chemotherapy and stem cell transplantation.

In order fight the cancer, T-cells collected from the patient are sent to a lab, where they are genetically modified to include a gene that instructs the T-cells to target and kill cancer cells. Millions of such genetically modified T-cells are then infused back into the patient.

"With the US.Food and Drug Administration's recent approval of this therapy, we believe this is a major advance in the treatment of patients with relapsed or refractory large B-cell lymphoma and is likely to save or prolong lives of many patients," said Neelapu, a professor at the University of Texas.

The results, published in the New England Journal of Medicine, showed that out of the 111 patients with aggressive large B-cell lymphoma from 22 centers across the US, 42 percent of patients remained in remission at 15 months following treatment with ‘axi-cel’ marketed as Yescarta.

After being infused back into patients' bodies, these newly built ‘hunter’ cells both multiply and attack, targeting cells that express a protein called CD19.

These hunter cells can grow more than 10,000 new cells for each single engineered cell patients receive, producing high remission rates while surviving in the body for years.

However, while the therapy could potentially cure patients who have run out of other options, it also can cause severe side effects, cautioned Patrick Stiff, director at Loyola University in Chicago.

Hence, doctors need to carefully inform patients of the pros and cons of this new therapy as a treatment option.

© 2018 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.

For news, views and gossips, follow @IANSLIVE at Twitter. Find us on Facebook too!

Update: 23-December-2017



© 2018 IANS India Private Limited.
Don't forget to bookmark us! (CTRL-D)
Site designed by IANS